Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Michael J. Kelley(Durham VA Health Care System), Daniel L. Hertz(GTx (United States)), Stefanie D. Krens(University of North Carolina at Chapel Hill), Michael J. Morris(Dana-Farber Cancer Institute), Jai N. Patel(Levine Cancer Institute), Ivo Shterev(Statistical and Applied Mathematical Sciences Institute), Yoichi Furukawa(The University of Tokyo), Dorothy Watson(Indiana University Bloomington), Alexander B. Sibley(Duke University), Cameron Lassiter(University of Maryland, Baltimore), Cynthia L. Renn(University of Maryland, Baltimore), Kouros Owzar(Duke University), Sherrie Lessans(University of Maryland, Baltimore), Flora Mulkey(Sherwin Williams (United States)), Susan Halabi(Duke Medical Center), Deanna L. Kroetz(University of California, San Francisco), M. Eileen Dolan(National Institutes of Health), Phillip G. Febbo(Veracyte (United States)), Heather E. Wheeler(Loyola University Chicago), Claudia Wing(University of Chicago), Mark J. Ratain(University of Chicago), Michiaki Kubo(RIKEN Center for Integrative Medical Sciences), Lois S. Weisman(University of Michigan), Susan G. Dorsey(University of Maryland, Baltimore), Chen Jiang, Yusuke Nakamura(Yokohama University of Pharmacy), John F. Mahoney(University of Pittsburgh), William Kevin Kelly(Thomas Jefferson University), Paula N. Friedman(University of North Carolina at Chapel Hill), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Howard L. McLeod(University of North Carolina at Chapel Hill), Eric J. Small(CancerCare Manitoba)
Cited by 4
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k